Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

The present disclosure relates to bacteriophage ΦCJ28 (KCCM11466P) and a composition containing the same as an active ingredient. Further, the present disclosure relates to a method for preventing and/or treating infective diseases caused by enterotoxic Escherichia coli (ETEC) of animals excluding humans by using the composition. A bacteriophage ΦCJ28 (KCCM11466P) has a specific ability to kill enterotoxigenic Escherichia coli.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to polypeptides comprising the sequence of a peptidoglycan hydrolase and a peptide sequence heterologous to the peptidoglycan hydrolase wherein said heterologous peptide sequence comprises a specific sequence motif which is 16, 17, 18, 19 or 20 amino acids in length. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

Provided are a bacteriophage KFS-ST3 having specific killing ability for Salmonella typhimurium and its derived biofilm, and a pharmaceutical composition for preventing or treating infectious diseases caused by Salmonella, including the bacteriophage. The bacteriophage KFS-ST3 of the present disclosure has specific killing ability for Salmonella, but does not kill beneficial bacteria and has excellent acid resistance and heat resistance, and thus may be not only used for the prevention or treatment of infectious diseases caused by Salmonella typhimurium and its derived biofilm, but also widely used in antibiotic compositions, feed additive compositions, disinfectants, or cleaning agents.

The present invention relates to a Myoviridae bacteriophage ESC-COP-7 (accession number KCTC 13130BP) isolated from nature, and a method for preventing and treating infections from pathogenic Escherichia coli by means of a composition containing the Myoviridae bacteriophage ESC-COP-7 as an active ingredient, the Myoviridae bacteriophage ESC-COP-7 being characterized by having the capability to specifically kill Escherichia coli, and genome expressed by the SEQ ID 1.

Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to polypeptides comprising the sequence of a peptidoglycan hydrolase and a peptide sequence heterologous to the peptidoglycan hydrolase wherein said heterologous peptide sequence comprises a specific sequence motif which is 16, 17, 18, 19 or 20 amino acids in length. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

Methods and compositions are provided for preventing or reducing symptoms or disease associated with Xylella fastidiosa or Xanthomonas axonopodis in a plant. The invention provides novel bacteriophages virulent to Xylella fastidiosa or Xanthomonas axonopodis, including XfaMija and XfaMijo, and further provides methods for treating or preventing Pierce's Disease or Citrus Canker in plants.

The present invention relates to a Myoviridae bacteriophage Esc-COP-14 (Accession number: KCTC 13528BP) isolated from nature, and characterized by having the ability to specifically kill Escherichia coli and having the genome represented by SEQ. ID. NO: 1, and to a method for preventing and treating the infection of pathogenic Escherichia coli using the composition comprising Myoviridae bacteriophage Esc-COP-14 as an active ingredient.